Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple hip injection prevent Post-Surgery confusion in seniors?

NCT ID NCT07449468

Symptom relief Sponsor: Poznan University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a nerve block (PENG block) to standard spinal anesthesia can reduce confusion after hip replacement in people aged 75 and older. About 180 participants will be randomly assigned to receive either the nerve block or a placebo injection. The main goal is to see if the block lowers the rate of delirium within three days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ropivacaine
What this could lead to
If it works, this could provide a simple way to lower the risk of confusion after hip surgery in older adults.
What could go wrong
This is a small, early-stage trial. The nerve block may not reduce delirium, and there are always risks with any injection near nerves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

75 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 75 years * Scheduled for elective primary total hip arthroplasty * Planned spinal anesthesia * ASA physical status II-III * Ability to provide written informed consent * Ability to communicate and reliably assess pain using the Numeric Rating Scale (NRS) * Expected postoperative hospitalization ≥ 72 hours Exclusion Criteria: * Pre-existing delirium, acute psychosis, or active major psychiatric disorder * Documented severe dementia or inability to provide informed consent * Severe hearing or visual impairment preventing reliable CAM assessment * Contraindications to regional anesthesia (e.g., coagulopathy according to institutional standards, infection at the injection site, allergy to local anesthetics) * Pre-existing neurological deficits of the operative lower limb are interfering with assessment * Chronic opioid use (\>30 mg morphine milligram equivalents per day for \>2 weeks prior to surgery) * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) * Severe hepatic insufficiency * Participation in another interventional clinical trial within 30 days * Any other condition that, in the investigator's judgment, may interfere with study participation or protocol adherence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, hip

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Poznan University of Medical Sciences

    RECRUITING

    Poznan, 62-701, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.